dm+d
421552005
Articles
Advising on missed or delayed doses of medicines
15 October 2021Guidance to advise people who occasionally forget or are late in taking a dose of their medicine(s).
Safety in Lactation: Drugs affecting bone metabolism
18 September 2020Drugs used exclusively for postmenopausal osteoporosis have not been included. Bisphosphonates have very poor oral bioavailability in fasting adults, which is decreased even further in…
Do gastric adverse events influence the choice of bisphosphonate for the treatment of osteoporosis?
25 February 2020This updated Medicines Q&A evaluates the published evidence examining the gastric safety of bisphosphonates for the treatment of osteoporosis. Alendronate should be the first choice…
Is there an interaction between bisphosphonates and proton pump inhibitors?
21 June 2019This updated Medicines Q&A evaluates the evidence for an interaction between bisphosphonates and proton pump inhibitors.
Medicine Compliance Aid Stability
FosamaxMerck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Fosamax
Tablets 10mg, 70mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
No special precautions for storage. However complex administration regime makes it unsuitable for MCA.
19 February 2015
Lactation Safety Information
Sodium alendronate
Sodium alendronate
No published evidence of safety
Negligible levels anticipated in milk, due to drug’s properties, with subsequent minimal absorption from the infant’s GI tract
8 July 2021